home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550149.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
2KB
|
31 lines
Document 0149
DOCN M9550149
TI Current and potential treatment of tuberculosis.
DT 9505
AU Houston S; Fanning A; Department of Medicine, University of Alberta,
Edmonton, Canada.
SO Drugs. 1994 Nov;48(5):689-708. Unique Identifier : AIDSLINE MED/95136883
AB A recent resurgence of interest in tuberculosis as a global health
problem has accompanied the resurgence of tuberculosis in both
industrialised and developing countries. It has also been demonstrated
recently that tuberculosis treatment and control is one of the most cost
effective of all medical interventions. The human immunodeficiency virus
(HIV) epidemic and increasing resistance to antituberculous drugs
complicate our response to the problem of tuberculosis. Chemotherapy
with currently available agents is highly effective, not only in
pulmonary tuberculosis in adults, but also in extrapulmonary disease,
and in disease in children and even patients with concomitant HIV
infection. Short course chemotherapy and intermittent therapy are as
effective as older regimens. Measures, including directly observed
therapy, to maximise compliance with therapy, are of utmost importance.
An efficient programme which assures compliance with effective
antituberculosis chemotherapy should be a priority for health spending
even in those countries with fewest resources.
DE Animal Antitubercular Agents/*THERAPEUTIC USE Human
Tuberculosis/*DRUG THERAPY/EPIDEMIOLOGY/MICROBIOLOGY JOURNAL ARTICLE
REVIEW REVIEW, ACADEMIC
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).